ILLUMINA INC (ILMN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ILMN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ILMN | Board Chair at Biogen; Director | 66 | ["Financial Expert","Deep knowledge of clinical markets","Audit committee financial expert under SEC rules","EVP and CFO, Public Service Enterprise Group, Inc. (2009–2015)","SVP of Global Human Health, Strategy and Integration, Merck & Co., Inc. (2008–2009)","SVP and CFO, Gilead Sciences, Inc. (2007–2008)","Various financial and operational positions at Merck & Co., Inc. (1987–2007)","Board Chair at Biogen","Director at Duke Energy"] | ["Audit","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BIIB | Independent Chair | 66 | ["Business Operations","Commercial","Cybersecurity","Executive Leadership","Finance","International Business","Public Board Service","Public Policy"] | ["Audit Committee","Corporate Governance Committee","Corporate Governance"] | 2025 |
Biography sourced from the proxy statement filing.
Profile Director since 2017 Financial Expert Age: 66 Board Committees Audit Compensation Education B.A. in History from Colgate University MBA in Finance and Accounting from Columbia University Relevant Expertise Ms. Dorsa s deep knowledge of clinical markets, especially as our technology and products are increasingly utilized in clinical settings, significantly enhances the Board s understanding of these markets and the risks and opportunities associated with operating in markets regulated by the U.S. Food and Drug Administration ( FDA ). In addition, as a result of her significant financial and accounting expertise, Ms. Dorsa is an audit committee financial expert under applicable US Securities and Exchange Commission ( SEC ) rules. Career Highlights EVP and CFO, Public Service Enterprise Group, Inc. (2009 2015) SVP of Global Human Health, Strategy and Integration, Merck & Co., Inc. (2008 2009) SVP and CFO, Gilead Sciences, Inc. (2007 2008) EVP and CFO, Avaya, Inc. (2007) Various financial and operational positions at Merck & Co., Inc. including Vice President and Treasurer (1987 2007) Public Board Service Biogen, Inc. (2010 Present; Chair 2023 Present) (1) Duke Energy Corporation (since 2021) Intellia Therapeutics, Inc (2015 2023) Goldman Sachs Funds (2016 2021) Public Service Enterprise Group, Inc. (2003 2009) Non-Public Board Service Founder and current board member emeritus, Institute for Advanced Clinical Trials for Children (since 2016) Junior Achievement of New Jersey (2009 2015) Of Note Named Best 50 Women in Business by NJBIZ (2014) (1) Ms. Dorsa announced on February 11, 2026 that she would be retiring from the Biogen board effective immediately following Biogen s 2026 Annual Meeting of Stockholders, scheduled to take place on June 9, 2026